Pediatric Crohn’s disease poses challenges due to longer cumulative duration of disease and its effect on patient growth. A “top-down” approach, with early introduction of biologics, is common in pediatrics. Anti-TNF agents are commonly used, but anti-IL 12/23 antibody ustekinumab has recently emerged as an alternative for refractory Crohn’s treatment.